NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_AR_agonist_AUC_viability,"Data from the assay component ACEA_AR_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,181.662087612353,6.7609249015637065,14.156843138433839,1.15096641999155,8.95647120560566,180.771514628203,percent_activity,2,26.869413616817,,0.874118768317139,0.874118768317139,0.803586403409589,20,cell cycle
ACEA_AR_antagonist_80hr,"Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",, , , ,,,Active,2.86287634840823,7.821036620118479,9.25935838839341,0.966580894021645,0.122016065451132,2.85986524216955,log2_fold_induction,1.30102999566398,0.366048196353396,,0.862349596012678,0.862349596012678,0.847300579921695,20,nuclear receptor
ACEA_AR_antagonist_AUC_viability,"Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,160.389512917726,5.540075049185949,13.854152708723381,1.14157997037967,9.65026114229828,160.27898187455,percent_activity,2,28.9507834268948,,0.963405111555151,0.963405111555151,0.882819370359849,20,cell cycle
ACEA_ER_AUC_viability,"Data from the assay component ACEA_ER_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,106.55735079408134,5.327867539704068,27.050814675292,1.4321803490601877,5.860768439731081,106.55418011692386,percent_activity,2,20,"[""Only highest conc above baseline, active""]",1.3524681786477988,1.3439593810319774,1.3126331943847402,20,cell cycle
APR_HepG2_CellCycleArrest_72h_dn,"Data from the assay component APR_HepG2_CellCycleArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,1.2544669157627,1.3528534312526368,12.980181951536252,1.11328078029134,0.0927274815425616,1.40503613805643,log2_fold_induction,1.69897000433602,0.927274815425616,,1.19843848997788,1.01064732191819,0.933660774017363,20,cell cycle
APR_HepG2_CellLoss_24h_dn,"Data from the assay component APR_HepG2_CellLoss_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,3.83232328337117,5.78881793664713,47.15222147997395,1.67350215844699,0.066202173316075,3.22265036976172,log2_fold_induction,2,0.66202173316075,,1.3651248833574,1.10122021589316,1.24090225997416,20,cell cycle
APR_HepG2_CellLoss_72h_dn,"Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,5.33376414400747,6.010692096052399,34.298961875977,1.53528097548424,0.0887379366431112,4.90406578493625,log2_fold_induction,2,0.887379366431112,,1.1776819030489,0.881510950433007,1.04772939724408,20,cell cycle
APR_HepG2_MicrotubuleCSK_24h_dn,"Data from the assay component APR_HepG2_MicrotubuleCSK_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MicrotubuleCSK_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of conformation reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",, , , ,,,Active,1.07642236709024,1.3159828558445348,83.07383557751197,1.91946426261033,0.0817960782930902,0.89701863924319,log2_fold_induction,2,0.817960782930902,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.98200632262106,1.85324362200914,1.80018394893008,20,cell morphology
APR_HepG2_MitoMass_24h_dn,"Data from the assay component APR_HepG2_MitoMass_24hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,4.07267901871749,8.184809509193716,46.251372954710334,1.66512462913569,0.0497589957853361,3.39389918228396,log2_fold_induction,2,0.497589957853361,,1.21725524859582,0.922696589242947,1.16609568551606,20,cell morphology
APR_HepG2_MitoticArrest_24h_up,"Data from the assay component APR_HepG2_MitoticArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",, , , ,,,Active,1.51175726684945,1.3715493920742243,20.074438291635463,1.3026434020077,0.110222590275308,1.54013606951065,log2_fold_induction,2,1.10222590275308,,1.45633279992542,1.10502305962544,0.961567580445721,20,cell cycle
APR_HepG2_MitoticArrest_72h_up,"Data from the assay component APR_HepG2_MitoticArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",, , , ,,,Active,4.71981645188284,3.326003004317509,29.727867435649323,1.47316375568497,0.141906560088972,4.26957365256638,log2_fold_induction,2,1.41906560088972,,1.26707741816336,0.908916690266922,0.936745768375312,20,cell cycle
APR_HepG2_NuclearSize_24h_dn,"Data from the assay component APR_HepG2_NuclearSize_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,0.348435144645451,1.3246751638476526,55.38130951417004,1.74336322060519,0.0102845399297649,0.332974857517591,log2_fold_induction,2,0.263034405833794,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.83740945931617,1.54844713553105,1.55967117741973,20,cell morphology
APR_HepG2_p53Act_24h_up,"Data from the assay component APR_HepG2_p53Act_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",NP_000537.3, , , ,"[46,46]",,Active,1.439076803263947,1.4807530964201103,50.8797479102495,1.7065449508821262,0.09718546641861357,1.3168315502548,log2_fold_induction,2,0.9718546641861358,,1.7971120876220827,1.537118305387712,1.4348410407757535,20,dna binding
APR_HepG2_p53Act_72h_up,"Data from the assay component APR_HepG2_p53Act_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",NP_000537.3, , , ,"[46,46]",,Active,2.45068801831475,2.073870299276605,35.889747817902524,1.55497040674009,0.118169782322915,2.04224001528426,log2_fold_induction,2,1.18169782322915,,1.53398914292392,1.03179127177097,0.908119697103078,20,dna binding
APR_HepG2_P-H2AX_24h_up,"Data from the assay component APR_HepG2_P-H2AX_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",NP_002096.1, , , ,,,Active,1.84122402759571,2.2423057812132106,52.17203082744818,1.7174377422234,0.0821129768750588,1.53435335645706,log2_fold_induction,2,0.821129768750588,,1.67797422290781,1.37770336649165,1.31779469156702,20,dna binding
APR_HepG2_P-H2AX_72h_up,"Data from the assay component APR_HepG2_P-H2AX_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",NP_002096.1, , , ,,,Active,4.73447291710503,4.317332327418399,40.49447414913277,1.60739576370176,0.109661998615151,3.94539409775954,log2_fold_induction,2,1.09661998615151,,1.30189071862313,0.946383070075067,1.04761836530466,20,dna binding
APR_HepG2_StressKinase_72h_up,"Data from the assay component APR_HepG2_StressKinase_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""stress response"".",NP_002219.1, , , ,,,Active,3.29600127123344,3.0294338711005104,58.4379902494527,1.76669527162603,0.108799248027028,2.74666772604104,log2_fold_induction,2,1.08799248027028,,1.66134667340071,1.43802765409331,1.43964153599638,20,cell cycle
ATG_AP_1_CIS_up,"Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.","NP_005243.1|NP_002219.1", , , ,,,Active,1.7904333193085389,2.985079678659062,25.690954624308187,1.4097802420774248,0.11995882938125292,1.7898425215966958,log2_fold_induction,1.84509804001426,0.5997941469062646,"[""Only one conc above baseline, active""]",1.3725578327956003,1.3348609520466466,1.2904993953381438,20,dna binding
ATG_DR4_LXR_CIS_dn,ATG_DR4_LXR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_009052.3|NP_005684.2", , , ,,,Active,1.7707592926326967,2.993672283322326,22.49792730293758,1.3521425091175507,0.11830014277097414,1.4756327438713446,log2_fold_induction,1.84509804001426,0.5915007138548707,,1.123523704614454,0.8936796909628268,0.6241096836479912,20,nuclear receptor
ATG_DR5_CIS_up,"Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR5_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_000955.1|NP_001277145.1|NP_000957.1", , , ,,,Active,1.1159833553800587,1.8801770208429114,3.093088653668201,0.49039236786839996,0.11871045577184501,0.9299861295058808,log2_fold_induction,1.30102999566398,0.593552278859225,,0.5788760577226464,-0.03498481920654556,-1.032879108820162,20,nuclear receptor
ATG_EGR_CIS_up,"Data from the assay component ATG_EGR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_EGR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EGR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_001955.1, , , ,,,Active,0.9884047762288972,1.4167238441938754,20.403726214982324,1.309709487368454,0.13953386614895374,0.9883559090188128,log2_fold_induction,1.84509804001426,0.6976693307447688,,1.3572284760650217,1.2929689778327385,1.1904290920156415,20,dna binding
ATG_ERa_TRANS_up,"Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,3.871842739356672,3.503444620574127,11.666592608305985,1.066944032781516,0.22103062321117403,3.4526163875588263,log2_fold_induction,1.84509804001426,1.10515311605587,,0.693951633101501,0.4260738035476306,0.17386680156128353,20,nuclear receptor
ATG_ERE_CIS_up,"Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,2.4379707242392525,4.824697965705735,19.750122619896693,1.295569796315856,0.10106210757931403,2.031642270216775,log2_fold_induction,1.84509804001426,0.5053105378965701,,0.36535158348482344,-0.057842728964515144,-0.22804522581153064,20,nuclear receptor
ATG_FXR_TRANS_up,"Data from the assay component ATG_FXR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_FXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001193922.1, , , ,"[27,61,27,61]",[479],Active,1.2820384396889126,1.5476682950650902,30.68163112518376,1.4868784442546572,0.16567354177595192,1.068365366459617,log2_fold_induction,1.84509804001426,0.8283677088797596,"[""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.629000102159903,1.3789863871345456,0.9682258408881527,20,nuclear receptor
ATG_IR1_CIS_dn,ATG_IR1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_001193922.1, , , ,,,Active,0.7109484332623601,1.4512914016294927,57.249249130387774,1.7577697949303932,0.09797459455270192,0.5924570372680796,log2_fold_induction,1.84509804001426,0.4898729727635096,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.8009710458850312,1.7387752344152183,1.6384663300393667,20,nuclear receptor
ATG_MRE_CIS_up,"Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_MRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005946.2, , , ,,,Active,1.3987760507249658,2.325742509002865,22.611029194233335,1.354320330731192,0.12028640705584168,1.3986071547814358,log2_fold_induction,1.84509804001426,0.6014320352792084,,1.3390126956837591,1.2969663482513307,1.23503816780779,20,dna binding
ATG_NF_kB_CIS_up,"Data from the assay component ATG_NF_kB_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NF_kB_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFKB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is NF-kappa B.",NP_068810.3, , , ,,,Active,0.8562136635809028,1.337638596185581,24.405376959626675,1.387485520053242,0.12801868397375604,0.8560213609549276,log2_fold_induction,1.84509804001426,0.6400934198687802,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.446430443150753,1.3762736995414437,1.2682023048053905,20,dna binding
ATG_NRF2_ARE_CIS_up,"Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006155.2, , , ,"[61,61]",[478],Active,1.9585644007006038,2.5220106593146054,33.09073428356841,1.5197064042636228,0.15531769411576343,1.9536970023633573,log2_fold_induction,1.84509804001426,0.7765884705788172,"[""Only one conc above baseline, active""]",1.496903215869109,1.456503129622781,1.4004209816741484,20,dna binding
ATG_Oct_MLP_CIS_up,"Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Oct_MLP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.",NP_002688.3, , , ,,,Active,1.454086828780654,2.1456515178953506,26.260875349062655,1.419309198255048,0.13553802345377633,1.21173902398778,log2_fold_induction,1.84509804001426,0.6776901172688816,,1.3770098075961608,1.1249378935785639,0.7357843200353638,20,dna binding
ATG_PBREM_CIS_up,"Data from the assay component ATG_PBREM_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PBREM_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001070948.1, , , ,"[8,107,58,8,107,58]","[456,715]",Active,0.693631744130691,1.446817261386953,13.935230087693164,1.1441141438416116,0.09588380822409588,0.5780264535107763,log2_fold_induction,1.84509804001426,0.4794190411204794,"[""Less than 50% efficacy""]",1.5438571043075058,0.9731451902091912,0.053847293581905875,20,nuclear receptor
ATG_PXRE_CIS_up,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,"[8,11,60,8,11,60]",,Active,2.4689002424562014,3.7048042487784443,1.897421309675412,0.2781637737731094,0.13328100901796647,2.24201799144542,log2_fold_induction,1.30102999566398,0.6664050450898323,,0.04986229711847617,-0.09898739485129676,-0.2259716249755871,20,nuclear receptor
ATG_PXR_TRANS_up,"Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,"[8,11,60,8,11,60]",,Active,2.2690481176551964,1.7616168346458885,4.038778431176975,0.6062500282735651,0.2576097222766731,2.611053655454441,log2_fold_induction,1.30102999566398,1.2880486113833656,,0.669858047527296,0.4519345634387808,0.09301057651310307,20,nuclear receptor
ATG_RARg_TRANS_up,"Data from the assay component ATG_RARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000957.1, , , ,,,Active,1.7607773586175384,1.5232643739634717,0.91177753479226,-0.04011111254637308,0.23118473571807732,2.072510471814053,log2_fold_induction,1.30102999566398,1.1559236785903866,,0.284387268261636,-0.25604605437154904,-1.140976563663921,20,nuclear receptor
ATG_RORE_CIS_up,"Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.","NP_599023.1|NP_008845.2|NP_005051.2", , , ,,,Active,1.1301263496045433,1.6506025668488626,26.53322386560787,1.4237900212594443,0.13693500450105905,0.9417719580785814,log2_fold_induction,1.84509804001426,0.6846750225052953,,1.5488800327593135,1.2607725026889312,0.7843883534970697,20,nuclear receptor
ATG_RXRb_TRANS_up,"Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_RXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_068811.1, , , ,,,Active,1.3281040915571172,1.336933337543467,7.166850070961681,0.8553283192127951,0.19867917932204862,1.3843863848252886,log2_fold_induction,1.84509804001426,0.9933958966102431,"[""Hit-call potentially confounded by overfitting""]",0.9985934407961963,0.8282564371053192,0.5659687502961609,20,nuclear receptor
ATG_VDRE_CIS_up,"Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000367.1, , , ,,,Active,1.7313774505927655,2.3842413543872283,9.209347700890476,0.9642288701603334,0.1452350826317871,1.442814542172651,log2_fold_induction,1.84509804001426,0.7261754131589355,,0.7630125613016248,0.2898083282043181,-0.39549552055369097,20,nuclear receptor
ATG_Xbp1_CIS_up,"Data from the assay component ATG_Xbp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Xbp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene XBP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_005071.2, , , ,,,Active,1.077165938831156,1.8287609233218876,30.544785877537674,1.4849370850244277,0.11780281666064009,0.8976382823703245,log2_fold_induction,1.84509804001426,0.5890140833032005,"[""Only one conc above baseline, active""]",1.5317560016642688,1.3062518669864336,0.937233293662378,20,dna binding
BSK_3C_Eselectin_down,"Data from the assay component BSK_3C_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2, , , ,,,Active,0.9321969742092577,11.77295156038051,39.99999999999999,1.6020599913279623,0.022749058062569997,1.035778235,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.0373264362889714,20,cell adhesion molecules
BSK_3C_HLADR_down,"Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2, , , ,,,Active,1.4347394399832107,18.119687572487354,10,1,0.025758990402599997,1.1485085499999999,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,0.8464005023080949,20,cell adhesion molecules
BSK_3C_ICAM1_down,"Data from the assay component BSK_3C_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_000192.2, , , ,,,Active,1.4990250764470403,18.93156714843093,39.99999999999999,1.6020599913279623,0.016926969131288997,1.23447675,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.1952893387600498,20,cell adhesion molecules
BSK_3C_IL8_down,"Data from the assay component BSK_3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1, , , ,,,Active,0.780246699312673,7.898700592911678,39.99999999999999,1.6020599913279623,0.0329272175904,0.78012365,log10_fold_induction,1.60205999132796,0.0987816527712,"[""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.0041224392859274,20,cytokine
BSK_3C_MCP1_down,"Data from the assay component BSK_3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,1.016656919222077,11.994066571575392,39.99999999999999,1.6020599913279623,0.028254440453399997,0.8340776,log10_fold_induction,1.60205999132796,0.08476332136019998,"[""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.0701753066502455,20,cytokine
BSK_3C_MIG_down,"Data from the assay component BSK_3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1, , , ,,,Active,1.6198244184641497,20.457172617489256,39.99999999999999,1.6020599913279623,0.00716423639925,1.34134165,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.3418132586520959,20,cytokine
BSK_3C_Proliferation_down,"Data from the assay component BSK_3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.2796210613488186,10.89472401207664,10,1,0.0391510930713,1.2792477,log10_fold_induction,1.60205999132796,0.1174532792139,,1,1,0.7835195735200893,20,cell cycle
BSK_3C_SRB_down,"Data from the assay component BSK_3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.954415322867342,12.053552709858769,10,1,0.02172150128694,0.775471985,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,0.9276382273362536,20,cell cycle
BSK_3C_TissueFactor_down,"Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1, , , ,,,Active,0.6416562837009665,4.928589785670392,39.99999999999999,1.6020599913279623,0.04339688170481999,0.476714555,log10_fold_induction,1.60205999132796,0.13019064511446,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.9579621622040777,20,cytokine
BSK_3C_uPAR_down,"Data from the assay component BSK_3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1, , , ,,,Active,0.602216759790287,5.136500834206146,10,1,0.0390808697223,0.591816515,log10_fold_induction,1.60205999132796,0.1172426091669,,1,1,0.8051684076279801,20,cytokine
BSK_3C_VCAM1_down,"Data from the assay component BSK_3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,1.4973623721690115,18.91056843521254,10,1,0.0189344513925,1.28846275,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,1.0145759845068194,20,cell adhesion molecules
BSK_4H_Eotaxin3_down,"Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_006063.1, , , ,,,Active,1.1557370857331013,14.210371721127231,39.99999999999999,1.6020599913279623,0.027110177186399995,1.1536629,log10_fold_induction,1.60205999132796,0.08133053155919999,"[""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.1387398039401804,20,cytokine
BSK_4H_MCP1_down,"Data from the assay component BSK_4H_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,0.3440612867215028,2.131510296413893,39.99999999999999,1.6020599913279623,0.05380555551,0.327663975,log10_fold_induction,1.60205999132796,0.16141666653,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.8550158658968954,20,cytokine
BSK_4H_Pselectin_down,"Data from the assay component BSK_4H_Pselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Pselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_002996.2, , , ,,,Active,0.703038359981518,5.734867448476825,10,1,0.04086338910171,0.56480368,log10_fold_induction,1.60205999132796,0.12259016730513,"[""Less than 50% efficacy""]",1,1,0.8017821016308229,20,cell adhesion molecules
BSK_4H_SRB_down,"Data from the assay component BSK_4H_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_4H_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.8431750664640906,10.648671352771457,39.99999999999999,1.6020599913279623,0.02048812375239,0.84240188,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.1031166129889427,20,cell cycle
BSK_4H_uPAR_down,"Data from the assay component BSK_4H_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1, , , ,,,Active,0.6922896968099588,6.26255838476961,39.99999999999999,1.6020599913279623,0.03684807679098,0.57320695,log10_fold_induction,1.60205999132796,0.11054423037293999,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.3974912576992646,20,cytokine
BSK_4H_VCAM1_down,"Data from the assay component BSK_4H_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,1.2997072781533074,16.41433221916687,39.99999999999999,1.6020599913279623,0.0228833401839,1.07168655,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.1502818355239413,20,cell adhesion molecules
BSK_4H_VEGFRII_down,"Data from the assay component BSK_4H_VEGFRII was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VEGFRII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",NP_002244.1, , , ,"[43,43]",,Active,0.43989680379150387,4.203772123662775,39.99999999999999,1.6020599913279623,0.03488111715312,0.32744627000000004,log10_fold_induction,1.60205999132796,0.10464335145935999,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.0036248998192616,20,kinase
BSK_BE3C_IP10_down,"Data from the assay component BSK_BE3C_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2, , , ,,,Active,0.35373953765120797,4.226294925305024,39.99999999999999,1.6020599913279623,0.027899893713299997,0.35346754,log10_fold_induction,1.60205999132796,0.08369968113989999,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.0934801922538246,20,cytokine
BSK_BE3C_MMP1_up,"Data from the assay component BSK_BE3C_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",NP_002412.1, , , ,,,Active,0.12628756857780554,1.372439640652253,39.99999999999999,1.6020599913279623,0.030672282369078,0.126246205,log10_fold_induction,1.60205999132796,0.092016847107234,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,0.8558749340024453,20,protease
BSK_BE3C_PAI1_down,"Data from the assay component BSK_BE3C_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",NP_000593.1, , , ,,,Active,0.23196797326698662,2.0735644560498527,39.99999999999999,1.6020599913279623,0.0372897295428,0.18893706,log10_fold_induction,1.60205999132796,0.11186918862840001,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.4024433934175602,20,cytokine
BSK_CASM3C_HLADR_down,"Data from the assay component BSK_CASM3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2, , , ,,,Active,0.6039557997481022,5.739761128656554,39.99999999999999,1.6020599913279623,0.03507438644283,0.45341750000000003,log10_fold_induction,1.60205999132796,0.10522315932849,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.2071460286078544,20,cell adhesion molecules
BSK_CASM3C_IL8_down,"Data from the assay component BSK_CASM3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1, , , ,,,Active,0.15858497812511646,2.002809832390526,39.99999999999999,1.6020599913279623,0.016910900838509997,0.109551183,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.439093633441947,20,cytokine
BSK_CASM3C_LDLR_down,"Data from the assay component BSK_CASM3C_LDLR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_LDLR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""misc protein"" intended target family, where the subfamily is ""LDL receptor"".",NP_000518.1, , , ,"[57,57]",,Active,0.21943685213766334,2.771323553126198,39.99999999999999,1.6020599913279623,0.024506084431499996,0.174309205,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.4081902312736898,20,misc protein
BSK_CASM3C_MCP1_down,"Data from the assay component BSK_CASM3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,0.9666119321411053,11.086001829255062,39.99999999999999,1.6020599913279623,0.029064037905,0.624537565,log10_fold_induction,1.60205999132796,0.08719211371499999,"[""Only one conc above baseline, active"",""Noisy data""]",1.6020599913279623,1.6020599913279623,1.2925820112457724,20,cytokine
BSK_CASM3C_MCSF_down,"Data from the assay component BSK_CASM3C_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3, , , ,,,Active,0.5054447494906962,5.228984408128733,39.99999999999999,1.6020599913279623,0.03222070865265,0.36982034,log10_fold_induction,1.60205999132796,0.09666212595794998,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.0597944636670071,20,cytokine
BSK_CASM3C_MIG_down,"Data from the assay component BSK_CASM3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1, , , ,,,Active,0.12147185429548149,1.5340987968593007,39.99999999999999,1.6020599913279623,0.015950413476900002,0.0998218505,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.0915328777965496,20,cytokine
BSK_CASM3C_Proliferation_down,"Data from the assay component BSK_CASM3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_CASM3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.3244707189638947,13.619766667151781,39.99999999999999,1.6020599913279623,0.032415404055299996,1.0897112,log10_fold_induction,1.60205999132796,0.09724621216589999,"[""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.1683010723665332,20,cell cycle
BSK_CASM3C_SAA_down,"Data from the assay component BSK_CASM3C_SAA was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_SAA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""apolipoproteins"".",NP_954630.1, , , ,,,Active,0.28376215193271426,2.796535941910509,39.99999999999999,1.6020599913279623,0.033823053213809996,0.23043621,log10_fold_induction,1.60205999132796,0.10146915964143,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.076960660388774,20,cell adhesion molecules
BSK_CASM3C_SRB_down,"Data from the assay component BSK_CASM3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_CASM3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.18912676612312557,2.388529804259108,39.99999999999999,1.6020599913279623,0.015242156257229997,0.1334882,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.4624278190537225,20,cell cycle
BSK_CASM3C_uPAR_down,"Data from the assay component BSK_CASM3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1, , , ,,,Active,0.39170804343295296,3.661188331332678,39.99999999999999,1.6020599913279623,0.0356631060723,0.29286644,log10_fold_induction,1.60205999132796,0.1069893182169,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.4236821671150977,20,cytokine
BSK_CASM3C_VCAM1_down,"Data from the assay component BSK_CASM3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,0.9166122708435892,10.627611723811802,39.99999999999999,1.6020599913279623,0.028749396529979997,0.5680554600000001,log10_fold_induction,1.60205999132796,0.08624818958993999,"[""Noisy data"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.5019002364792478,20,cell adhesion molecules
BSK_hDFCGF_CollagenIII_down,"Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""collagen"".",NP_000081.1, , , ,,,Active,0.7825984293418505,5.529027291940458,10,1,0.047181200117099996,0.7825987249999999,log10_fold_induction,1.60205999132796,0.14154360035129998,,1,1,0.8987956040928011,20,cell adhesion molecules
BSK_hDFCGF_IL8_down,"Data from the assay component BSK_hDFCGF_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1, , , ,,,Active,1.0243720054941763,12.937053363343782,40.000000000000014,1.6020599913279625,0.008495260327134,1.1056146,log10_fold_induction,1.60205999132796,0.07918124604762482,,1.6020599913279625,1.6020599913279625,1.0452826359137972,20,cytokine
BSK_hDFCGF_IP10_down,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2, , , ,,,Active,1.2691110443815135,15.69012502932303,10,1,0.0269619913164,1.26849905,log10_fold_induction,1.60205999132796,0.0808859739492,"[""Noisy data""]",1,1,0.7534836848456173,20,cytokine
BSK_hDFCGF_MCSF_down,"Data from the assay component BSK_hDFCGF_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3, , , ,,,Active,1.0121008738613082,9.465253378492385,10,1,0.0356426758443,0.98830465,log10_fold_induction,1.60205999132796,0.10692802753289998,"[""Noisy data""]",1,1,0.7261197439500792,20,cytokine
BSK_hDFCGF_MIG_down,"Data from the assay component BSK_hDFCGF_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1, , , ,,,Active,1.1183197403861591,14.12354308889668,10,1,0.015977820005069997,1.16434985,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,0.8237348133361245,20,cytokine
BSK_hDFCGF_MMP1_down,"Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",NP_002412.1, , , ,,,Active,0.8334922077818158,10.484418198205416,40.000000000000014,1.6020599913279625,0.026499394689809996,0.83341378,log10_fold_induction,1.60205999132796,0.07949818406942999,"[""Noisy data""]",1.6020599913279625,1.6020599913279625,0.9758189429548002,20,protease
BSK_hDFCGF_PAI1_down,"Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",NP_000593.1, , , ,,,Active,1.1141835815034076,6.726625577183755,10,1,0.055212605920499994,1.1140541,log10_fold_induction,1.60205999132796,0.1656378177615,,1,1,0.8155827072047988,20,cytokine
BSK_hDFCGF_Proliferation_down,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.1430897282422945,8.435863589809626,4,0.6020599913279624,0.0451678604517,1.1464001000000001,log10_fold_induction,1,0.1355035813551,,0.6020599913279624,0.6020599913279624,0.528938730970903,20,cell cycle
BSK_hDFCGF_SRB_down,"Data from the assay component BSK_hDFCGF_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.7758794326902656,9.798777758859725,10,1,0.024374730148650003,0.775833585,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,0.7078669949698478,20,cell cycle
BSK_hDFCGF_TIMP1_down,"Data from the assay component BSK_hDFCGF_TIMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_TIMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",NP_003245.1, , , ,,,Active,0.777123923735934,5.7915449020943,10,1,0.0447274971171,0.7770874000000001,log10_fold_induction,1.60205999132796,0.1341824913513,,1,1,0.8475015776071906,20,protease inhibitor
BSK_hDFCGF_VCAM1_down,"Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,1.2602927923289573,8.919302790545707,10,1,0.04709982465089999,1.2602338,log10_fold_induction,1.60205999132796,0.14129947395269998,,1,1,0.7035770015954323,20,cell adhesion molecules
BSK_KF3CT_ICAM1_down,"Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_000192.2, , , ,,,Active,1.1303781199427778,14.275831416733375,10,1,0.02073805097175,1.0665544,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,0.968732902106679,20,cell adhesion molecules
BSK_KF3CT_IL1a_down,"Data from the assay component BSK_KF3CT_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000566.3, , , ,,,Active,1.1790587298690034,13.73483120672387,10,1,0.0286148093637,0.936433725,log10_fold_induction,1.60205999132796,0.08584442809109999,,1,1,0.9462195060842631,20,cytokine
BSK_KF3CT_IP10_down,"Data from the assay component BSK_KF3CT_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2, , , ,,,Active,1.0178183105812557,12.854285091309029,10,1,0.0138351257877,1.01779132,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,0.9287637616954724,20,cytokine
BSK_KF3CT_MCP1_down,"Data from the assay component BSK_KF3CT_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,1.1600891995134766,10.096131899423272,10,1,0.0383014409568,0.9105021499999999,log10_fold_induction,1.60205999132796,0.1149043228704,,1,1,0.7943371016927054,20,cytokine
BSK_KF3CT_MMP9_down,"Data from the assay component BSK_KF3CT_MMP9 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MMP9_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",AAM97934.1, , , ,,,Active,0.8469930895308689,10.11899283656562,10,1,0.027901099882530003,0.8457648799999999,log10_fold_induction,1.60205999132796,0.08370329964759,,1,1,0.7290527456471227,20,protease
BSK_KF3CT_SRB_down,"Data from the assay component BSK_KF3CT_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_KF3CT_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.6312386399868326,7.9720725739421185,40.000000000000014,1.6020599913279625,0.00501083847705,0.5230913699999999,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,1.1043354968116255,20,cell cycle
BSK_KF3CT_TGFb1_down,"Data from the assay component BSK_KF3CT_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TGFb1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",P01137.2, , , ,,,Active,0.901690911867296,8.445760578720632,10,1,0.0355875157113,0.8098084999999999,log10_fold_induction,1.60205999132796,0.10676254713389999,,1,1,0.7754567291662542,20,growth factor
BSK_KF3CT_TIMP2_down,"Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TIMP2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",, , , ,,,Active,1.0378919999509548,11.289846741336,10,1,0.030643817220029995,0.8552426,log10_fold_induction,1.60205999132796,0.09193145166008998,,1,1,0.715122147183207,20,protease inhibitor
BSK_KF3CT_uPA_down,"Data from the assay component BSK_KF3CT_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_002649.1, , , ,,,Active,1.1642714744562759,14.70387917052993,10,1,0.020151273081261,1.03413165,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,1.015047028716581,20,protease
BSK_LPS_CD40_down,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1, , , ,,,Active,0.7183612292129341,5.204435554024847,40.000000000000014,1.6020599913279625,0.0460095510042,0.579491575,log10_fold_induction,1.60205999132796,0.13802865301259998,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,1.4052368657271697,20,cytokine
BSK_LPS_Eselectin_down,"Data from the assay component BSK_LPS_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2, , , ,,,Active,0.949302098975037,11.98897651097918,40.000000000000014,1.6020599913279625,0.0245760564798,0.94900428,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.0445902758866117,20,cell adhesion molecules
BSK_LPS_IL1a_down,"Data from the assay component BSK_LPS_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000566.3, , , ,,,Active,0.415429330741253,3.3661768413562037,40.000000000000014,1.6020599913279625,0.041137602124499996,0.41742604,log10_fold_induction,1.60205999132796,0.1234128063735,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.9832557517088214,20,cytokine
BSK_LPS_IL8_down,"Data from the assay component BSK_LPS_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1, , , ,,,Active,0.8510738398926101,9.588877909603276,40.000000000000014,1.6020599913279625,0.029585451252860995,0.699544125,log10_fold_induction,1.60205999132796,0.08875635375858298,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.1398816690346187,20,cytokine
BSK_LPS_MCP1_down,"Data from the assay component BSK_LPS_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,1.0293661814843673,11.479093044928764,40.000000000000014,1.6020599913279625,0.029891042711459998,0.8350805,log10_fold_induction,1.60205999132796,0.08967312813438,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.4005739567792808,20,cytokine
BSK_LPS_MCSF_down,"Data from the assay component BSK_LPS_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3, , , ,,,Active,0.7388691224139725,7.089918738234552,40.000000000000014,1.6020599913279625,0.0347380155633,0.504562945,log10_fold_induction,1.60205999132796,0.1042140466899,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.1065099013814725,20,cytokine
BSK_LPS_SRB_down,"Data from the assay component BSK_LPS_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_LPS_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.2017959199985722,15.1777848920909,10,1,0.018219059086199998,0.9761875200000001,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,1.0134468263021073,20,cell cycle
BSK_LPS_TissueFactor_down,"Data from the assay component BSK_LPS_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1, , , ,,,Active,0.586362099223481,4.837767069994366,40.000000000000014,1.6020599913279625,0.0404017039776,0.47653775,log10_fold_induction,1.60205999132796,0.1212051119328,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.3934198616689595,20,cytokine
BSK_LPS_TNFa_down,"Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_000585.2, , , ,,,Active,1.8831419165282288,13.830189512271074,40.000000000000014,1.6020599913279625,0.04538722854225,1.3059056,log10_fold_induction,1.60205999132796,0.13616168562675,"[""Only one conc above baseline, active"",""Noisy data""]",1.6020599913279625,1.6020599913279625,1.4511181000698121,20,cytokine
BSK_LPS_VCAM1_down,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,1.0520611910554103,13.286747096940498,40.000000000000014,1.6020599913279625,0.0224178208338,1.05169765,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.050611033374597,20,cell adhesion molecules
BSK_SAg_CD38_down,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""other cytokine"".",NP_001766.2, , , ,,,Active,0.6361295904928995,8.033841625961395,10,1,0.0243080164845,0.6306076,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,0.9597893271577689,20,cytokine
BSK_SAg_CD40_down,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1, , , ,,,Active,0.8722313997130902,8.748687981723391,40.000000000000014,1.6020599913279625,0.0332328459435,0.7223759249999999,log10_fold_induction,1.60205999132796,0.09969853783049999,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.9933333921622576,20,cytokine
BSK_SAg_CD69_down,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001772.1, , , ,,,Active,0.5399285079488819,5.099483308544144,40.000000000000014,1.6020599913279625,0.03529302057225,0.5398757,log10_fold_induction,1.60205999132796,0.10587906171674999,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.9766697077269356,20,cytokine
BSK_SAg_Eselectin_down,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2, , , ,,,Active,0.9123229825967223,7.950079198932275,40.000000000000014,1.6020599913279625,0.038252154885,0.754688655,log10_fold_induction,1.60205999132796,0.114756464655,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.3977764894072833,20,cell adhesion molecules
BSK_SAg_IL8_down,"Data from the assay component BSK_SAg_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1, , , ,,,Active,0.5451744101715614,3.6292791938950995,40.000000000000014,1.6020599913279625,0.050071872038999994,0.45785553,log10_fold_induction,1.60205999132796,0.150215616117,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.1115024947082688,20,cytokine
BSK_SAg_MCP1_down,"Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,0.9581206711624901,10.064794315288362,40.000000000000014,1.6020599913279625,0.031731751991099996,0.79709348,log10_fold_induction,1.60205999132796,0.09519525597329999,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.3959391530928735,20,cytokine
BSK_SAg_MIG_down,"Data from the assay component BSK_SAg_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1, , , ,,,Active,1.1612567639272466,14.665805628125508,40.000000000000014,1.6020599913279625,0.00921114872622,1.1560063,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.1899328621605736,20,cytokine
BSK_SAg_PBMCCytotoxicity_down,"Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_PBMCCytotoxicity_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,0.6741714931272347,8.514282444125008,10,1,0.0217234984974,0.6741186,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,0.9584337168826194,20,cell cycle
BSK_SAg_Proliferation_down,"Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.0442295187429966,8.725198025346149,10,1,0.0398932500141,1.0407,log10_fold_induction,1.60205999132796,0.1196797500423,,1,1,0.8435553659495052,20,cell cycle
BSK_SAg_SRB_down,"Data from the assay component BSK_SAg_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.159604399678215,14.644937501750762,10,1,0.017346765986949,0.9264216000000001,log10_fold_induction,1.60205999132796,0.07918124604762482,,1,1,0.9231878600708563,20,cell cycle
CCTE_Padilla_ZF_144hpf_TERATOSCORE_up,"Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defect  as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""malformation"" intended target family, where the subfamily is ""total"".",, , , ,,,Active,55.8616659331322,2.79308329665661,0.8003856759465556,-0.0967006922909919,1.53481347591287,67.552798325,percent_activity,1.47712125471966,20,,-0.206330756008633,-0.549130614882916,-0.50921439623854,20,malformation
CCTE_Shafer_MEA_acute_cross_correlation_area_up,"Data from the assay component CCTE_Shafer_MEA_acute_cross_correlation_area was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_cross_correlation_area_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,64.15080590600193,1.2815095971139838,5.932587028038679,0.7732441178155873,16.68625971808883,50.961832942566545,percent_activity,1.60205999132796,50.05877915426649,"[""Only one conc above baseline, active"",""Borderline active""]",1.689644895778774,1.689644895778774,-0.8152350550710961,20,neuroactivity
CCTE_Shafer_MEA_acute_cross_correlation_HWHM_dn,"Data from the assay component CCTE_Shafer_MEA_acute_cross_correlation_HWHM was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_cross_correlation_HWHM_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,39.97303759029448,1.3088334879715642,11.197760374799401,1.0491311696229915,10.180321626765236,43.0379746835443,percent_activity,1.60205999132796,30.54096488029571,"[""Only one conc above baseline, active"",""Borderline active""]",1.1129199355273718,1.1129199355273718,0.9298427881530614,20,neuroactivity
CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,30.087439166440586,1.4583176037688041,3.6162867982019637,0.5582628659231659,6.877203129753559,29.098079298383144,percent_activity,1.60205999132796,20.631609389260674,,0.7768055508363348,0.7768055508363348,-0.05720975953676166,20,neuroactivity
CCTE_Shafer_MEA_dev_AB_dn,"Data from the CCTE_Shafer_MEA_dev_AB was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_AB_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,100.591686430982,5.157071175366578,6.353995962969526,0.803046934560909,6.50186142549743,100,percent activity,1.30102999566398,19.5055842764923,"[""Noisy data""]",0.725698501821085,0.725698501821085,0.683766620578703,20,cell cycle
CCTE_Shafer_MEA_dev_AB_dn,"Data from the CCTE_Shafer_MEA_dev_AB was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_AB_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,100.591686430982,5.157071175366578,6.353995962969526,0.803046934560909,6.50186142549743,100,percent activity,1.30102999566398,19.5055842764923,"[""Noisy data""]",0.725698501821085,0.725698501821085,0.683766620578703,20,cell cycle
CCTE_Shafer_MEA_dev_active_electrodes_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_active_electrodes_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_active_electrodes_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.171109485704,3.7836113120190364,4.148752171453537,0.617917492726101,8.825,100,percent_activity,1,26.475,,0.549090389535704,0.549090389535704,0.470197118574917,20,neurodevelopment
CCTE_Shafer_MEA_dev_active_electrodes_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_active_electrodes_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_active_electrodes_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.171109485704,3.7836113120190364,4.148752171453537,0.617917492726101,8.825,100,percent_activity,1,26.475,,0.549090389535704,0.549090389535704,0.470197118574917,20,neurodevelopment
CCTE_Shafer_MEA_dev_burst_duration_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_burst_duration_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_burst_duration_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999998449485,1.6591957070313623,4.379635484856988,0.641437965868733,24.1080659223316,100,percent_activity,-1,72.3241977669948,"[""Noisy data""]",0.78591146415351,0.78591146415351,-0.120295183018769,20,neurodevelopment
CCTE_Shafer_MEA_dev_burst_duration_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_burst_duration_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_burst_duration_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999998449485,1.6591957070313623,4.379635484856988,0.641437965868733,24.1080659223316,100,percent_activity,-1,72.3241977669948,"[""Noisy data""]",0.78591146415351,0.78591146415351,-0.120295183018769,20,neurodevelopment
CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn,"Data from the CCTE_Shafer_MEA_dev_bursting_electrodes_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.596361327582,2.623584224560352,5.758902203258668,0.760339703474213,12.7810344827586,100,percent activity,1,38.3431034482758,,0.73403035041068,0.73403035041068,0.641059388868449,20,neurodevelopment
CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn,"Data from the CCTE_Shafer_MEA_dev_bursting_electrodes_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.596361327582,2.623584224560352,5.758902203258668,0.760339703474213,12.7810344827586,100,percent activity,1,38.3431034482758,,0.73403035041068,0.73403035041068,0.641059388868449,20,neurodevelopment
CCTE_Shafer_MEA_dev_burst_rate_dn,"Data from the assay component CCTE_Shafer_MEA_dev_burst_rate was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_burst_rate_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.077834471387,1.3663007840328945,4.462831357801212,0.649610475959924,24.4157644839102,100,percent_activity,1,73.2472934517306,,0.704131285608543,0.704131285608543,0.530328979376718,20,neurodevelopment
CCTE_Shafer_MEA_dev_burst_rate_dn,"Data from the assay component CCTE_Shafer_MEA_dev_burst_rate was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_burst_rate_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.077834471387,1.3663007840328945,4.462831357801212,0.649610475959924,24.4157644839102,100,percent_activity,1,73.2472934517306,,0.704131285608543,0.704131285608543,0.530328979376718,20,neurodevelopment
CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn,"Data from the CCTE_Shafer_MEA_dev_correlation_coefficient_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn  in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999934503,2.3530511741502766,2.1661534625026606,0.335689221244598,16.9992052946372,100,percent activity,1,50.9976158839116,,0.0970272765148416,0.0970272765148416,-1.39863451559188,20,neurodevelopment
CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn,"Data from the CCTE_Shafer_MEA_dev_correlation_coefficient_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn  in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999934503,2.3530511741502766,2.1661534625026606,0.335689221244598,16.9992052946372,100,percent activity,1,50.9976158839116,,0.0970272765148416,0.0970272765148416,-1.39863451559188,20,neurodevelopment
CCTE_Shafer_MEA_dev_firing_rate_mean_dn,"Data from the CCTE_Shafer_MEA_dev_firing_rate_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_firing_rate_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.99999993635,1.6978287763972375,2.939393902065136,0.468257788873039,23.5595017205814,100,percent activity,1,70.6785051617442,,0.649852774670279,0.649852774670279,-0.640762414324663,20,neurodevelopment
CCTE_Shafer_MEA_dev_firing_rate_mean_dn,"Data from the CCTE_Shafer_MEA_dev_firing_rate_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_firing_rate_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.99999993635,1.6978287763972375,2.939393902065136,0.468257788873039,23.5595017205814,100,percent activity,1,70.6785051617442,,0.649852774670279,0.649852774670279,-0.640762414324663,20,neurodevelopment
CCTE_Shafer_MEA_dev_interburst_interval_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_interburst_interval_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.86953254674,1.5602891288640741,6.043003198689836,0.781252824129803,21.5493249895668,100,percent_activity,1,64.6479749687004,,0.812701299797709,0.812701299797709,0.661972509787967,20,neurodevelopment
CCTE_Shafer_MEA_dev_interburst_interval_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_interburst_interval_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.86953254674,1.5602891288640741,6.043003198689836,0.781252824129803,21.5493249895668,100,percent_activity,1,64.6479749687004,,0.812701299797709,0.812701299797709,0.661972509787967,20,neurodevelopment
CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.279323718951,1.1888829979827458,6.352919559155904,0.802973356321271,28.3962127730534,100,percent_activity,-0.522878745280338,85.1886383191602,"[""Borderline active""]",0.893449252618103,0.893449252618103,0.683693036429353,20,neurodevelopment
CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_up,"Data from the assay component CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,98.5129598794351,1.156409608407581,0.03539998840543939,-1.45099688021869,28.3962127730534,108.762066842066,percent_activity,-0.522878745280338,85.1886383191602,"[""Hit-call potentially confounded by overfitting"",""Borderline active""]",-1.24022407632318,-1.24022407632318,-1.70061738458455,20,neurodevelopment
CCTE_Shafer_MEA_dev_LDH_dn,"Data from the assay component CCTE_Shafer_MEA_dev_LDH was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_LDH_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,100.435628405985,4.203233257656257,6.038968846116961,0.780962789172087,7.96495001580351,99.688570538773,percent_activity,1.30102999566398,23.8948500474105,,0.717764211162185,0.717764211162185,0.661682461529656,20,cell cycle
CCTE_Shafer_MEA_dev_LDH_dn,"Data from the assay component CCTE_Shafer_MEA_dev_LDH was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_LDH_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,100.435628405985,4.203233257656257,6.038968846116961,0.780962789172087,7.96495001580351,99.688570538773,percent_activity,1.30102999566398,23.8948500474105,,0.717764211162185,0.717764211162185,0.661682461529656,20,cell cycle
CCTE_Shafer_MEA_dev_mutual_information_norm_dn,"Data from the CCTE_Shafer_MEA_dev_mutual_information_norm was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_mutual_information_norm_dn  in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999934784,1.6582294996929758,0.7064573225538596,-0.150914068973513,24.1221133658926,100,percent activity,1,72.3663400976778,,0.303204260021897,0.303204260021897,-2.53684442997676,20,neurodevelopment
CCTE_Shafer_MEA_dev_mutual_information_norm_dn,"Data from the CCTE_Shafer_MEA_dev_mutual_information_norm was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_mutual_information_norm_dn  in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999934784,1.6582294996929758,0.7064573225538596,-0.150914068973513,24.1221133658926,100,percent activity,1,72.3663400976778,,0.303204260021897,0.303204260021897,-2.53684442997676,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_duration_std_dn,"Data from the CCTE_Shafer_MEA_dev_network_spike_duration_std was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_duration_std_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.23304132667,1.3219213191420873,6.323075374341564,0.800928358859796,25.5267440053011,100,percent activity,-1,76.5802320159033,,0.862459646293202,0.862459646293202,0.681648035941304,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_duration_std_dn,"Data from the CCTE_Shafer_MEA_dev_network_spike_duration_std was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_duration_std_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.23304132667,1.3219213191420873,6.323075374341564,0.800928358859796,25.5267440053011,100,percent activity,-1,76.5802320159033,,0.862459646293202,0.862459646293202,0.681648035941304,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_number_dn,"Data from the CCTE_Shafer_MEA_dev_network_spike_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_number_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.646547219605,1.2857377064517739,5.817533140821969,0.764738866017231,26.0930739643514,100,percent activity,1,78.2792218930542,,0.83274292276355,0.83274292276355,0.645458550495394,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_number_dn,"Data from the CCTE_Shafer_MEA_dev_network_spike_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_number_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.646547219605,1.2857377064517739,5.817533140821969,0.764738866017231,26.0930739643514,100,percent activity,1,78.2792218930542,,0.83274292276355,0.83274292276355,0.645458550495394,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_peak_dn,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_peak was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_peak_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.114677915628,3.693516800502227,4.222766731574405,0.625597091373256,9.03517192629845,100,percent_activity,1,27.1055157788953,,0.564597694813839,0.564597694813839,0.490329710473502,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_peak_dn,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_peak was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_peak_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.114677915628,3.693516800502227,4.222766731574405,0.625597091373256,9.03517192629845,100,percent_activity,1,27.1055157788953,,0.564597694813839,0.564597694813839,0.490329710473502,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_burst_interspike_interval was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.156963700663,1.4444477654363979,4.870178168176711,0.687544849518661,23.1130923289574,100,percent_activity,1,69.3392769868722,,0.731567926145404,0.731567926145404,0.568262727209902,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_burst_interspike_interval was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.156963700663,1.4444477654363979,4.870178168176711,0.687544849518661,23.1130923289574,100,percent_activity,1,69.3392769868722,,0.731567926145404,0.731567926145404,0.568262727209902,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn,"Data from the CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.058762141253,2.9500983184470093,4.299704348646382,0.633438594145684,11.305698018671,100,percent activity,1,33.917094056013,,0.597180685472255,0.597180685472255,0.514155499895629,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn,"Data from the CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.058762141253,2.9500983184470093,4.299704348646382,0.633438594145684,11.305698018671,100,percent activity,1,33.917094056013,,0.597180685472255,0.597180685472255,0.514155499895629,20,neurodevelopment
CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.279323718951,1.1888829979827458,6.352919559155904,0.802973356321271,28.3962127730534,100,percent_activity,-0.522878745280338,85.1886383191602,"[""Borderline active""]",0.893449252618103,0.893449252618103,0.683693036429353,20,neurodevelopment
CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_up,"Data from the assay component CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,98.5129598794351,1.156409608407581,0.03539998840543939,-1.45099688021869,28.3962127730534,108.762066842066,percent_activity,-0.522878745280338,85.1886383191602,"[""Hit-call potentially confounded by overfitting"",""Borderline active""]",-1.24022407632318,-1.24022407632318,-1.70061738458455,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999931019,2.2002915758650525,1.1023519312181589,0.0423202672795749,18.1794087728033,100,percent_activity,1,54.5382263184099,,-0.145181120130616,-0.145181120130616,-2.21432130613538,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.999999931019,2.2002915758650525,1.1023519312181589,0.0423202672795749,18.1794087728033,100,percent_activity,1,54.5382263184099,,-0.145181120130616,-0.145181120130616,-2.21432130613538,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.023481780447,1.8152109842357824,6.172605101852419,0.790468493462769,18.5512836905804,100,percent activity,1,55.6538510717412,,0.801559740733543,0.801559740733543,0.671188178529902,20,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.023481780447,1.8152109842357824,6.172605101852419,0.790468493462769,18.5512836905804,100,percent activity,1,55.6538510717412,,0.801559740733543,0.801559740733543,0.671188178529902,20,neurodevelopment
CCTE_Shafer_MEA_dev_spike_duration_mean_dn,"Data from the CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_spike_duration_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.058254001901,2.352905772646296,4.295733499011743,0.633037330536305,14.1751326048452,100,percent activity,1,42.5253978145356,,0.616626990101919,0.616626990101919,0.513743228876457,20,neurodevelopment
CCTE_Shafer_MEA_dev_spike_duration_mean_dn,"Data from the CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_spike_duration_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.058254001901,2.352905772646296,4.295733499011743,0.633037330536305,14.1751326048452,100,percent activity,1,42.5253978145356,,0.616626990101919,0.616626990101919,0.513743228876457,20,neurodevelopment
LTEA_HepaRG_ABCB1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000918.2, , , ,,,Active,0.784321820640712,2.0672953798666893,10.515387403100302,1.02182527739604,0.126465046759354,0.794216228508655,log2_fold_induction,1.47712125471966,0.379395140278062,,1.01076580281569,1.01076580281569,0.648710232820134,20,transporter
LTEA_HepaRG_ABCC2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000383.1, , , ,,,Active,0.570654177125328,1.3296859776535586,11.226757941457556,1.05025435898475,0.143054873284778,0.55373067180615,log2_fold_induction,1.47712125471966,0.429164619854334,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.25596734821105,1.25596734821105,0.642907870223193,20,transporter
LTEA_HepaRG_ABCG2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_004818.2, , , ,,,Active,1.91384782193285,3.1757979941695855,13.265116955951404,1.12271108342505,0.200878417062049,1.50219613184347,log2_fold_induction,2,0.602635251186147,,0.40728612861205,0.40728612861205,-0.899360451469955,20,transporter
LTEA_HepaRG_BCL2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000624.2, , , ,,,Active,0.556850621262747,1.172509891635128,37.97473657363907,1.57949476989462,0.15830729879421,0.55661592150585,log2_fold_induction,2,0.47492189638263,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.67489397045843,1.67489397045843,1.46021326731689,20,cell cycle
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1, , , ,"[57,57]",,Active,2.60061074259735,2.8877042998772895,36.082446704958514,1.55729597882653,0.300193564683644,2.57649598369862,log2_fold_induction,2,0.900580694050932,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.49708225182898,1.49708225182898,1.34906319408218,20,cyp
LTEA_HepaRG_CYP2B6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000758.1, , , ,,,Active,3.73219419457162,4.950804635152965,3.02360091841515,0.480524468585879,0.251285361310856,3.1738954479497,log2_fold_induction,1.47712125471966,0.753856083932568,,-0.0986395225828919,-0.0986395225828919,-0.44569688205989,20,cyp
LTEA_HepaRG_CYP2C19_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000760.1, , , ,,,Active,1.79493781826215,3.2006073737389196,7.13711332691419,0.853522592772444,0.186937207917646,1.41111089515399,log2_fold_induction,1.47712125471966,0.560811623752938,,0.563314317284461,0.563314317284461,0.0450710241547655,20,cyp
LTEA_HepaRG_CYP2C8_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000761.3, , , ,,,Active,1.34386806593776,2.0757959047580816,9.059264911958069,0.957092959527578,0.215799646271804,0.920173866444596,log2_fold_induction,1.47712125471966,0.647398938815412,,0.852986074418235,0.852986074418235,-2.17381060104825,20,cyp
LTEA_HepaRG_CYP2E1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000764.1, , , ,,,Active,3.3631990638978,7.022355566195563,24.857616215573334,1.39545947852684,0.159642493756543,2.77163695762682,log2_fold_induction,2,0.478927481269629,,0.565750938100498,0.565750938100498,0.380100049486031,20,cyp
LTEA_HepaRG_CYP3A4_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_059488.2, , , ,,,Active,2.52727794992104,2.1298824867292776,4.207023848376589,0.62397497391122,0.395526977922934,2.72326000449088,log2_fold_induction,1.47712125471966,1.1865809337688,,0.604742703250613,0.604742703250613,0.277923377203104,20,cyp
LTEA_HepaRG_CYP3A5_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000768.1, , , ,,,Active,1.86644668307285,2.4412998227253198,80.2596533266537,1.90449727951137,0.254843296413747,1.07804090431857,log2_fold_induction,2,0.764529889241241,"[""Only highest conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.77477971823423,1.77477971823423,1.12478935794354,20,cyp
LTEA_HepaRG_CYP3A7_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000756.3, , , ,,,Active,1.93888429943752,2.4982807445423454,10.99034138016966,1.04101118261651,0.258695812266514,1.76883046424904,log2_fold_induction,2,0.776087436799542,,0.852945143713131,0.852945143713131,0.0189863501419987,20,cyp
LTEA_HepaRG_CYP4A11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000769.2, , , ,,,Active,2.97624311951495,4.6560807984241785,64.46439486726986,1.8093199102601,0.213072127136213,1.99528881279802,log2_fold_induction,2,0.639216381408639,,1.11232302638326,1.11232302638326,0.627995916675647,20,cyp
LTEA_HepaRG_CYP4A22_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001010969.2, , , ,,,Active,2.67140607411108,3.307255194855484,53.41981727985094,1.72770239820261,0.269247045935707,1.7849250073403,log2_fold_induction,2,0.807741137807121,,1.29902566015754,1.29902566015754,0.601107832886118,20,cyp
LTEA_HepaRG_CYP7A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000771.2, , , ,,,Active,0.927180255868602,1.7262019113079814,22.128431813472215,1.3449506376558,0.179040518530855,0.79071017143438,log2_fold_induction,2,0.537121555592565,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.46625498929568,1.46625498929568,0.511845754120054,20,cyp
LTEA_HepaRG_EGR1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001955.1, , , ,,,Active,0.63591581911887,1.2043948167412006,16.394612761364513,1.21470116314697,0.175998714673843,0.583726005870031,log2_fold_induction,2,0.527996144021529,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy""]",1.76252936689493,1.76252936689493,0.456560302524729,20,dna binding
LTEA_HepaRG_EZR_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_003370.2, , , ,,,Active,0.944760893766891,2.0002021806779244,122.02468149652276,2.08644768275361,0.15744423287028,0.53588488045122,log2_fold_induction,2,0.47233269861084,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy""]",2.08627878603659,2.08627878603659,0.25075529491642,20,membrane protein
LTEA_HepaRG_FABP1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001434.1, , , ,,,Active,1.22841535349852,2.545442266834695,6.914366504431746,0.83975239612535,0.160864691309103,1.16034499971134,log2_fold_induction,2,0.482594073927309,,0.65667035567636,0.65667035567636,-0.0843528215060894,20,transporter
LTEA_HepaRG_FASN_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_004095.4, , , ,"[58,34,34,58]",,Active,1.29001087088197,3.5098928194735137,50.93684629686085,1.70703205255791,0.122511895873739,0.913871782294911,log2_fold_induction,2,0.367535687621217,,1.19948983074858,1.19948983074858,0.495191465101282,20,lyase
LTEA_HepaRG_GSTA2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000837.3, , , ,,,Active,1.273862051514,1.9364127106250146,87.52110791040118,1.94211280666221,0.219282119719688,0.947785588056167,log2_fold_induction,2,0.657846359159064,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.94567939433675,1.94567939433675,1.82283248686895,20,transferase
LTEA_HepaRG_HSPA1A_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_005337.2, , , ,,,Active,0.539124736623908,1.13725838125224,15.484519497593183,1.18989773324582,0.158018835916096,0.48583744597576,log2_fold_induction,2,0.474056507748288,"[""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.92613826975737,1.92613826975737,0.375307956474081,20,dna binding
LTEA_HepaRG_ICAM1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000192.2, , , ,,,Active,1.09898005049331,1.920551410801807,71.21631686794954,1.85257950928084,0.190740368332464,0.859065659979485,log2_fold_induction,2,0.572221104997392,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.97241922381468,1.97241922381468,-1.32822551857903,20,cell adhesion molecules
LTEA_HepaRG_IGF1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,, , , ,,,Active,0.689817194791528,1.4171005053395571,21.045406198170486,1.32315731249894,0.162260237763032,0.597771795208575,log2_fold_induction,2,0.486780713289096,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.71009802163585,1.71009802163585,0.350869632212266,20,growth factor
LTEA_HepaRG_MYC_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002458.2, , , ,,,Active,0.719853700442251,1.5320061398906772,30.217427015808,1.4802574818293,0.15662550379718,0.719806769571624,log2_fold_induction,2,0.46987651139154,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.51451867239096,1.51451867239096,1.36097448341069,20,dna binding
LTEA_HepaRG_SLC22A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003048.1, , , ,,,Active,1.40836961176694,2.5299316446897318,73.86496071305987,1.86843847117256,0.185560957048395,0.95513177004376,log2_fold_induction,2,0.556682871145185,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.30574385149558,1.30574385149558,-1.03913303842706,20,transporter
LTEA_HepaRG_SLCO1B1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_006437.3, , , ,,,Active,0.857152873719855,1.5795507487577796,66.79304272539181,1.82473122799458,0.180885371867909,0.561902080341586,log2_fold_induction,2,0.542656115603727,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active""]",2.0049921791926,2.0049921791926,1.09865917251129,20,transporter
LTEA_HepaRG_THRSP_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003242.1, , , ,,,Active,3.084112846754,3.173535276701904,51.7182919740105,1.71364417362307,0.323940818661091,2.17484800061819,log2_fold_induction,2,0.971822455983273,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.35986016148489,1.35986016148489,0.712371656726999,20,growth factor
LTEA_HepaRG_UGT1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000454.1, , , ,,,Active,1.88640559001997,2.8481079437317396,8.426747494003246,0.92565998055895,0.220778803248623,1.52434398132835,log2_fold_induction,1.47712125471966,0.662336409745869,,0.646882095759413,0.646882095759413,-0.0716945260495632,20,transferase
OT_AR_ARSRC1_0480,"Data from the assay component OT_AR_ARSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_005408.1, , , ,,,Active,85.4860306926736,4.27430153463368,91.74919432622288,1.96260225928694,2.45637869822485,55.6737588652482,percent_activity,2,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.89821242478092,1.83443620905629,1.84332194458958,20,nuclear receptor
OT_AR_ARSRC1_0960,"Data from the assay component OT_AR_ARSRC1_0960 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0960, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_005408.1, , , ,,,Active,47.38509477517,2.3692547387585003,83.8153904447015,1.92332377246683,1.6382320441989,37.4599786552828,percent_activity,2,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.9062632272276,1.80624997044975,1.80404336327228,20,nuclear receptor
OT_ER_ERbERb_1440,"Data from the assay component OT_ER_ERbERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001428.1, , , ,,,Active,51.9948058750364,2.59974029375182,64.22274022456682,1.80768883189102,1.48426296250401,40.4642103554618,percent_activity,2,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.73477749089828,1.44020277421786,1.46671712397662,20,nuclear receptor
TAMU_HCS_1.5hr_SingleDonor1434_Cytotoxicity,"Data from the assay component  TAMU_HCS_1.5hr_Cytotoxicity was analyzed into 1 assay endpoint. This assay endpoint,  TAMU_HCS_1.5hr_Cytotoxicity, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,91.5350252202712,9.15350252202712,34.932498866496054,1.5432296536340202,14.95626666312798,91.21599770024076,percent_activity,2,10,"[""Only highest conc above baseline, active"",""Noisy data""]",1.330071692278329,1.5392398383803734,1.3200380365175692,20,cell cycle
TAMU_PeakParms_SingleDonor1434_Asystole,"Data from the assay component TAMU_PeakParms_SingleDonor1434_Asystole was analyzed into 1 assay endpoint. This assay endpoint, TAMU_PeakParms_SingleDonor1434_Asystole, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand changes in the cardiac function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cardiomyocyte function intended target family, where the subfamily is cessation of beating.",, , , ,,,Active,101.35949857691438,1.0669420902833093,69.08851508769045,1.839405858537818,9.724331715171544,100,percent_activity,2,95,"[""Borderline active"",""Only highest conc above baseline, active""]",1.9950747117212233,1.7872456254255815,1.7129085881151855,20,cardiomyocyte function
TAMU_PeakParms_SingleDonor1434_Chronotropy_Positive,"Data from the assay component TAMU_PeakParms_SingleDonor1434_Chronotropy was analyzed into 2 assay endpoints. This assay endpoint, TAMU_PeakParms_SingleDonor1434_Chronotropy_Positive, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand changes in the cardiac function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cardiomyocyte function intended target family, where the subfamily is elevated beat rate.",, , , ,,,Active,253.06873652437224,50.61374730487445,24.669193601864684,1.392154953300668,8.715639461504102,74.07194780585895,percent_activity,1,5,"[""Borderline active"",""Noisy data"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",-0.190033766336148,0.5164694655967884,0.501738624935143,20,cardiomyocyte function
TOX21_AP1_BLA_Agonist_ch1,"Data from the assay component TOX21_AP1_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,73.0439658248222,3.6521982912411097,31.199789375036534,1.49415166217331,2.57591984669775,72.5475078746,percent_activity,1.90308998699194,20,,1.44120091156659,1.37828073935641,1.37487134456816,20,channel 1
TOX21_AP1_BLA_Agonist_ratio,"Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_002219.1, , , ,,,Active,50.7159196876091,2.535795984380455,53.693670265592786,1.72992309145838,2.7369041511147,40.9673872585,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.67728651299122,1.52821090449059,1.46036311832024,20,dna binding
TOX21_AP1_BLA_Agonist_viability,"TOX21_AP1_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle target family, where the subfamily is cytotoxicity.",, , , ,,,Active,77.212957155322,3.4224671112935825,30.313012256275176,1.48162909510325,3.76010222277627,77.0009884906,percent_activity,1.90308998699194,22.5606133366576,,1.43359685879594,1.38578164136581,1.36234878114107,20,cell cycle
TOX21_ARE_BLA_agonist_viability,"TOX21_ARE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,66.4396820266391,2.244738066864892,61.81413408286265,1.79108778985191,4.93299441089742,44.5248343197,percent_activity,1.95424250943932,29.5979664653845,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.73782304645771,1.48702172639443,1.25650042299321,20,cell cycle
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,,,Active,73.9502318206189,2.3018354892915243,50.94625973169045,1.70711230536867,5.35443940025589,65.1823429821,percent_activity,1.95424250943932,32.1266364015353,,1.67612039867342,1.55649097494327,1.44895238983886,20,nuclear receptor
TOX21_CASP3_CHO,"The assay component endpoint  TOX21_CASP3_CHO was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. The TOX21_CASP3_CHO assay is a homogeneous, luminescent assay that measures caspase-3 activity following chemical treatment as an indicator of induction of apoptosis. Gain-of-signal activity can be used to understand changes in apoptosis. To generalize the intended target to other relatable targets, this assay endpoint is annotated to apoptosis, where the subfamily is caspase.",NP_116786.1, , , ,,,Active,30.5393836423066,1.52696918211533,74.73994272111395,1.87355276068095,0.87784491667383,25.2363317181,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.90832976818717,1.74540764898946,1.75427189913621,20,apoptosis
TOX21_CASP3_CHO_viability,"The assay component endpoint  TOX21_CASP3_CHO_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,86.9966793175922,4.3498339658796095,72.30397619549879,1.8591621810052,2.57636017956492,71.455264722,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.78249448202143,1.71153333671847,1.71981678432463,20,cell cycle
TOX21_DT40_100,"Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,57.4335192161481,2.662732195129044,63.45299032328242,1.80245209373252,3.59489896137582,50.7458641293,percent_activity,1.95424250943932,21.5693937682549,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.77484921584126,1.72294774292075,1.68317139269451,20,cell cycle
TOX21_DT40_657,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,46.6104858660287,1.7788893482405326,48.251247424475565,1.68350854550496,4.36700254498032,44.401552283,percent_activity,1.95424250943932,26.2020152698819,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.69707410601796,1.6325255579123,1.56422795841264,20,cell cycle
TOX21_ERa_BLA_Antagonist_ch1,"Data from the assay component TOX21_ERa_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,64.9713535411299,2.7067322354943033,59.295550584421385,1.77302210602646,4.00060219534206,47.3159285637,percent_activity,1.90308998699194,24.0036131720524,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.70169159666807,1.57491997057296,1.47984057755367,20,channel 1
TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780,"Data from the assay component TOX21_ERa_LUC_VM7_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1.  Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,,,Active,87.9876459920488,4.39938229960244,2.4142171542180333,0.382776331476755,0.53381416222722,82.7180196384,percent_activity,1.60205999132796,20,"[""Noisy data"",""Noisy data""]",0.048086075079865,-0.708042457192275,-0.218231694303146,20,nuclear receptor
TOX21_ERb_BLA_Agonist_ch2,"Data from the assay component TOX21_ERb_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,117.493130019448,5.8746565009724,8.863806526000698,0.947620267961148,1.20109945587492,104.086125934,percent_activity,1.60205999132796,20,"[""Noisy data"",""Noisy data""]",0.401782820306927,-0.242358342934209,0.190492824189484,20,channel 2
TOX21_ERb_BLA_Agonist_ratio,"Data from the assay component TOX21_ERb_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_001428.1, , , ,,,Active,96.2477987159877,4.812389935799385,8.477417393906768,0.928263566595774,0.95171634960297,89.7308927357,percent_activity,1.60205999132796,20,"[""Noisy data"",""Noisy data""]",0.597320063132499,0.06577713019662,0.384901869277567,20,nuclear receptor
TOX21_ERb_BLA_Agonist_viability,"TOX21_ERb_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,64.5169246499773,3.1395435217530583,48.22493663206262,1.68327166565001,3.42496311979521,61.6308137792,percent_activity,1.95424250943932,20.5497787187713,,1.64198151878245,1.59295179917964,1.56399133399322,20,cell cycle
TOX21_ERb_BLA_Antagonist_ratio,"Data from the assay component TOX21_ERb_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_001428.1, , , ,,,Active,49.1888355131269,2.028193297040323,17.898042405401977,1.25280553271041,4.04208970819059,45.9334771381,percent_activity,1.60205999132796,24.2525382491435,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.24616081586056,0.985796543939521,0.727688104217011,20,nuclear receptor
TOX21_ERb_BLA_Antagonist_viability,"TOX21_ERb_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,52.7570581019927,2.5038992038923755,79.49454714730241,1.90033733966206,3.51166013525229,36.171730964,percent_activity,1.95424250943932,21.0699608115137,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.87818499730314,1.82497410209851,1.78105701962993,20,cell cycle
TOX21_ERR_Antagonist,"Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_004442.3, , , ,,,Active,66.1515565686262,3.13055275260029,44.18438141468344,1.64526877921022,3.52182515338437,57.0053848427,percent_activity,1.95424250943932,21.1309509203062,,1.52491644896071,1.38108206694844,1.29565537124747,20,nuclear receptor
TOX21_ERR_viability,"TOX21_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,39.4156093529336,1.97078046764668,83.38980052631827,1.92111293497803,2.25399102610353,25.1859087508,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.92272280627852,1.83563067055746,1.80183262097646,20,cell cycle
TOX21_ESRE_BLA_ch1,"Data from the assay component TOX21_ESRE_BLA_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATF6. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,76.4565548232755,3.7133821285455957,61.29471631863021,1.78742303940321,3.43157765511288,53.2891282793,percent_activity,1.90308998699194,20.5894659306773,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.65000118375258,1.53129154337154,1.48493062648266,20,channel 1
TOX21_ESRE_BLA_ratio,"Data from the assay component TOX21_ESRE_BLA_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ATF6.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.",NP_031374.2, , , ,,,Active,75.3978216352357,3.7698910817617852,65.79609377583459,1.81820011090944,1.43781423195858,62.3915042417,percent_activity,1.90308998699194,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.76289227419304,1.66608134273834,1.69891979675784,20,dna binding
TOX21_ESRE_BLA_viability,"TOX21_ESRE_BLA_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,81.1386943320077,1.8218569611728974,24.8078959755902,1.39458993215051,7.42270991093352,78.315090149,percent_activity,1.90308998699194,44.5362594656011,,1.41510365337944,1.29293726459365,1.16484579451151,20,cell cycle
TOX21_FXR_BLA_agonist_viability,"TOX21_FXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,81.998233085904,1.532961151960562,29.978774972676888,1.47681388223219,8.9150153371503,77.248496541,percent_activity,1.90308998699194,53.4900920229018,,1.51097693801052,1.43742463414768,1.35753356843277,20,cell cycle
TOX21_FXR_BLA_Antagonist_ch1,"Data from the assay component TOX21_FXR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter,increased activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,59.1780148828792,2.8230174606520944,39.5549898335745,1.59720127722674,3.49378019015214,45.6755856953,percent_activity,1.90308998699194,20.9626811409128,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.44298842301245,1.20273690002963,1.03293119934918,20,channel 1
TOX21_FXR_BLA_Antagonist_ch2,"Data from the assay component TOX21_FXR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_FXR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,73.7517615803306,1.8391089583025004,32.52836236853106,1.51226219939581,6.68364982286526,59.5993846828,percent_activity,1.90308998699194,40.1018989371916,,1.55577602692689,1.26788294208684,0.967212989542115,20,channel 2
TOX21_FXR_BLA_antagonist_ratio,"Data from the assay component TOX21_FXR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_FXR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001193922.1, , , ,"[27,61,27,61]",[479],Active,96.4470522352844,4.82235261176422,27.25524391961097,1.43545007308054,2.78938673282934,79.9464656776,percent_activity,1.90308998699194,20,,0.977561264029562,0.631657541040385,0.685125678324915,20,nuclear receptor
TOX21_GR_BLA_Agonist_ch1,"Data from the assay component TOX21_GR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,85.8583122598516,3.9303766524504593,66.92842651509979,1.82561061487587,3.6408008634627,68.0616149071,percent_activity,1.90308998699194,21.8448051807762,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.76724518410767,1.72106413928655,1.70633030102146,20,channel 1
TOX21_GR_BLA_Agonist_ratio,"Data from the assay component TOX21_GR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000167.1, , , ,"[64,66,214,71,14,318,64,214,66,71,14,318]",,Active,176.036199995718,8.801809999785899,172.41066100167384,2.2365641168892,1.18637193543015,43.9397251153,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.87816600876011,1.55953714405105,1.85324144817722,20,nuclear receptor
TOX21_GR_BLA_Antagonist_ch2,"Data from the assay component TOX21_GR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,152.65758018767,3.062239713292918,71.0217173345881,1.8513911695133,8.30860168158384,108.9657400547,percent_activity,1.90308998699194,49.851610089503,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.81195172842895,1.76235297615312,1.73166446122988,20,channel 2
TOX21_GR_BLA_Antagonist_viability,"TOX21_GR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,119.688651441603,3.0762104633323117,58.5829132810981,1.76777096499743,6.48463712459766,90.7436317787,percent_activity,1.90308998699194,38.907822747586,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.68931292977276,1.59169768902637,1.53179634445336,20,cell cycle
TOX21_H2AX_HTRF_CHO_Agonist_ratio,"Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is histone.",NP_002096.1, , , ,,,Active,59.2598957012821,2.962994785064105,86.47361668871598,1.93688362336911,1.1538473582706,59.0237569101,percent_activity,2.30102999566398,20,,1.90026049012589,1.78593068848521,1.8175764662056,20,dna binding
TOX21_H2AX_HTRF_CHO_viability,"TOX21_H2AX_HTRF_CHO_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,76.8238094229155,3.841190471145775,80.50717536380543,1.90583458946144,2.15763115046871,76.2151416248,percent_activity,2.30102999566398,20,,1.84914702755359,1.77631313555968,1.78655423743094,20,cell cycle
TOX21_HRE_BLA_Agonist_ch1,"Data from the assay component TOX21_HRE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,86.0091972957242,4.300459864786211,32.36126908462983,1.51002554463506,2.28898316931438,85.4275963099,percent_activity,1.90308998699194,20,,1.44520373758942,1.37731997866201,1.3907452308448,20,channel 1
TOX21_HRE_BLA_Agonist_ratio,"Data from the assay component TOX21_HRE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is hypoxia-response element.",NP_001521.1, , , ,,,Active,131.801923527251,6.59009617636255,44.39697515500168,1.64735338186593,0.3624938875215,130.4347247446,percent_activity,1.90308998699194,20,,1.54638079695667,1.36636913430126,1.51844001904437,20,dna binding
TOX21_HRE_BLA_Agonist_viability,"TOX21_HRE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,98.9411919348829,4.947059596744145,39.31117383844889,1.59451601212204,3.0508964104962,98.779868509,percent_activity,1.90308998699194,20,,1.51998153398333,1.47055656538822,1.47523527010183,20,cell cycle
TOX21_HSE_BLA_agonist_ch1,"Data from the assay component TOX21_HSE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HSE_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,44.6694061138785,2.233470305693925,40.38092567176042,1.6061762702671,3.14273554940163,44.8759258551,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.59478518052288,1.53459855666013,1.48689593156499,20,channel 1
TOX21_HSE_BLA_agonist_ratio,"Data from the assay component TOX21_HSE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_HSE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is heat shock protein.",NP_005517.1, , , ,,,Active,41.2710024609328,2.0635501230466398,50.95335963750933,1.70717282472965,0.91844270028357,39.8967234063,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.70382807945494,1.56398980151517,1.58789251094602,20,dna binding
TOX21_HSE_BLA_agonist_viability,"TOX21_HSE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,84.4682455995392,1.8077303876974742,54.62753530159431,1.73741160635269,7.78768837934283,60.6382468838,percent_activity,1.90308998699194,46.726130276057,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.77477751903152,1.56916542945014,1.35291072779196,20,cell cycle
TOX21_MMP_ratio_down,"Data from the assay component TOX21_MMP_ratio was analyzed into 2 assay endpoints. This assay endpoint, TOX21_MMP_ratio_down, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of 6 membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.",, , , ,,,Active,90.5980521552282,2.3432440443521316,27.596354777460707,1.44085171958022,6.44391923052108,75.3985239991,percent_activity,1.95424250943932,38.6635153831265,,1.34029410763795,0.996255195713903,0.692098997419246,20,cell morphology
TOX21_NFkB_BLA_agonist_ch1,"Data from the assay component TOX21_NFkB_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_NFkB_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,79.139216578987,3.95696082894935,47.8967775026859,1.68030629504546,3.27484652838546,68.8065611373,percent_activity,1.90308998699194,20,,1.54885358238127,1.44341474940583,1.41389672465831,20,channel 1
TOX21_NFkB_BLA_agonist_viability,"TOX21_NFkB_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,85.9696060822098,3.503283691279791,38.1327455973058,1.58129807605341,4.08995358155937,89.5228948847,percent_activity,1.90308998699194,24.5397214893562,,1.5314843169004,1.48396978108257,1.46201776140073,20,cell cycle
TOX21_p53_BLA_p1_ch1,"Data from the assay component TOX21_p53_BLA_p1_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,69.9514315589813,3.497571577949065,78.87605445184234,1.89694517814196,3.00976293237186,51.9820708807,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.84725543249307,1.79330496923594,1.77766485796228,20,channel 1
TOX21_p53_BLA_p1_ratio,"Data from the assay component TOX21_p53_BLA_p1_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3, , , ,"[46,46]",,Active,51.1926902738511,2.559634513692555,83.65082325885346,1.92247021947675,1.19928273802848,32.6534727458,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.89834226364287,1.78228000005107,1.80318940562302,20,dna binding
TOX21_p53_BLA_p1_viability,"TOX21_p53_BLA_p1_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,100.416441623934,2.3935688755641418,70.91361498965986,1.85072962512978,6.99210027956454,73.6004374523,percent_activity,1.95424250943932,41.9526016773872,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.81490695037721,1.70699220041786,1.6135556190625,20,cell cycle
TOX21_p53_BLA_p3_viability,"TOX21_p53_BLA_p3_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,47.5534191784853,1.5777118807609378,59.83787640828414,1.77697617241441,5.02345831309728,39.6278494623,percent_activity,1.95424250943932,30.1407498785837,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.83860431892665,1.69071526313085,1.53018227522237,20,cell cycle
TOX21_p53_BLA_p4_ratio,"Data from the assay component TOX21_p53_BLA_p4_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3, , , ,"[46,46]",,Active,33.2119110622759,1.660595553113795,0.5712125722171011,-0.24320224243562,1.02079986237957,27.676592552,percent_activity,-0.154901959985743,20,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",-0.220694198167362,-0.367354545177976,-0.36248255611596,20,dna binding
TOX21_PGC_ERR_Antagonist,"Data from the assay component TOX21_PGC_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",NP_004442.3, , , ,,,Active,61.4583994010896,1.843322139986031,77.03230827206671,1.88667291168441,5.55685104879492,41.1419382724,percent_activity,1.95424250943932,33.3411062927695,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.90221631824827,1.79652693342473,1.686255654912,20,nuclear receptor
TOX21_PGC_ERR_viability,"TOX21_PGC_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,33.8419829910236,1.69209914955118,78.52108847243397,1.89498631123229,2.5904653717656,25.0776226746,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.91496527179106,1.82927984098907,1.77570599751371,20,cell cycle
TOX21_PPARd_BLA_agonist_ratio,"Data from the assay component TOX21_PPARd_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARd_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARD. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_006229.1, , , ,"[36,36]",,Active,52.5864513386934,2.62932256693467,74.97558949709119,1.87491988909415,2.9158737089685,33.1112782377,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.84841900490645,1.78742376476096,1.75563957499155,20,nuclear receptor
TOX21_PPARd_BLA_Agonist_viability,"TOX21_PPARd_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,91.8304308001559,2.754015087334112,26.464564817049382,1.42266475685334,5.55736672264977,90.300401738,percent_activity,1.90308998699194,33.3442003358986,,1.39216059120357,1.34091640488364,1.30338444291672,20,cell cycle
TOX21_PPARg_BLA_antagonist_viability,"TOX21_PPARg_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,76.5471239616543,1.397166187190873,39.7742187449251,1.59960165788241,9.1312358619699,78.5603658875,percent_activity,1.90308998699194,54.7874151718194,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.64973012460763,1.56786379614206,1.48032134376639,20,cell cycle
TOX21_PR_BLA_Agonist_viability,"TOX21_PR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,105.865024223245,3.1848409705883234,89.51050369971036,1.95187400102725,5.54004764031117,50.8480606375,percent_activity,1.95424250943932,33.240285841867,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.90944652185624,1.86063043016821,1.83259368658109,20,cell cycle
TOX21_PR_BLA_Antagonist_ch2,"Data from the assay component TOX21_PR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,70.2282347559411,1.690413840323484,26.54680859796645,1.42401231857753,6.92416585421295,66.3989665917,percent_activity,1.95424250943932,41.5449951252777,,1.50958016132713,1.22365370896436,0.916508971081935,20,channel 2
TOX21_PR_BLA_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3, , , ,,,Active,47.8479303502365,2.392396517511825,14.677870680412079,1.16666305702277,2.51198214229767,48.5857708006,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.09695992267442,0.81355019080772,0.704000710256858,20,nuclear receptor
TOX21_PR_BLA_Antagonist_viability,"TOX21_PR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,53.4522159252589,1.6257212592073713,76.74918942982605,1.88507379746502,5.47984631667627,42.1342697781,percent_activity,1.95424250943932,32.8790779000576,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.91052618376386,1.84101618931501,1.76579348319854,20,cell cycle
TOX21_PR_BLA_Followup_Agonist_viability,"TOX21_PR_BLA_Followup_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,85.9841332667587,1.8226798685019914,63.8286499321325,1.80501565857322,7.86242780503803,62.26154723,percent_activity,1.95424250943932,47.17456683022818,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.8356243933881307,1.652463386990681,1.4604544260598191,20,cell cycle
TOX21_PR_BLA_Followup_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3, , , ,,,Active,73.8394133388303,1.5310422965650663,38.074955752975036,1.5806394073134,8.03803325186715,66.716776045,percent_activity,1.95424250943932,48.2281995112029,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.64666182442034,1.505144786562052,1.3514358065947711,20,nuclear receptor
TOX21_PR_LUC_Followup_Antagonist,"Data from the assay component TOX21_PR_LUC_Followup_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_LUC_Followup_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is steroidal.",NP_000917.3, , , ,,,Active,66.6844072819654,1.3454273548555173,32.93743373821501,1.51768975886686,8.26062279781809,63.3279859852,percent_activity,1.95424250943932,49.5637367869085,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.61776100214126,1.46824274745275,1.31083689242048,20,nuclear receptor
TOX21_PXR_Agonist,"Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,,,Active,100.024916658329,5.00124583291645,90.78670016439274,1.95802223102906,1.80636679455099,49.3908045454,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.64339643877581,1.30912588171212,1.4594641419653,20,nuclear receptor
TOX21_PXR_viability,"The assay component endpoint  TOX21_PXR_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,31.8094962102748,1.59047481051374,75.81068777715991,1.87973043670646,2.43196946437473,25.8651257826,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.908330265279,1.81393949716678,1.76045012091681,20,cell cycle
TOX21_RAR_LUC_Agonist_viability,"TOX21_RAR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,90.7777994021507,4.538889970107535,71.901128380162,1.85673570603563,1.53553439731881,63.2551040767,percent_activity,1.95424250943932,20,,1.70105797088498,1.4959576868472,1.58607943332054,20,cell cycle
TOX21_RORg_LUC_CHO_Antagonist,"Data from the assay component TOX21_RORg_LUC_CHO_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RORg_LUC_CHO_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1F3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_005051.2, , , ,,,Active,101.967868962248,1.9569595677648408,65.10634259100607,1.81362329913805,8.68420845631059,71.6585697749,percent_activity,1.95424250943932,52.1052507378635,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.82135578006251,1.6256464281235,1.4274355443587,20,nuclear receptor
TOX21_RORg_LUC_CHO_Antagonist_viability,"TOX21_RORg_LUC_CHO_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,92.9728101891695,4.648640509458475,74.42055111079449,1.87169288180337,3.0881472477345,62.5499430206,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.73535305786824,1.6398359201959,1.64024996507272,20,cell cycle
TOX21_RT_HEK293_FLO_08hr_viability,"TOX21_RT_HEK293_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,210.247524040228,8.927462718195729,38.59717014032642,1.58655546432219,3.92510785122456,209.6311449047,percent_activity,1.90308998699194,23.5506471073474,,1.47416368821833,1.43321460977621,1.46727515056849,20,cell cycle
TOX21_RT_HEK293_FLO_16hr_viability,"TOX21_RT_HEK293_FLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,275.388551339946,10.981816806962073,36.935360902677715,1.56744234695456,4.17946253309319,273.3570422012,percent_activity,1.90308998699194,25.0767751985591,,1.40990684520394,1.35909977426416,1.41699636119963,20,cell cycle
TOX21_RT_HEK293_FLO_24hr_viability,"TOX21_RT_HEK293_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,342.721348984005,12.758440901022514,34.504128029519094,1.53787105661513,4.47705368342379,342.3084016015,percent_activity,1.90308998699194,26.8623221005427,,1.40407725742051,1.36418779651713,1.41859067018108,20,cell cycle
TOX21_RT_HEK293_FLO_32hr_viability,"TOX21_RT_HEK293_FLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,368.698234926078,12.968669986498938,34.06601378146636,1.53232131777697,4.73831980341741,368.2989324334,percent_activity,1.90308998699194,28.4299188205045,,1.39756393006004,1.35771291254014,1.41303954253921,20,cell cycle
TOX21_RT_HEK293_FLO_40hr_viability,"TOX21_RT_HEK293_FLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,381.7438932881,13.37669087528935,34.19543752272623,1.5339681648022,4.75633195144065,381.3119936035,percent_activity,1.90308998699194,28.5379917086439,,1.39739229647542,1.35761349380246,1.41468758882531,20,cell cycle
TOX21_RT_HEK293_GLO_08hr_viability,"TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,83.2235450411171,3.427828264978709,30.342838843313103,1.48205621047543,4.04646609105207,83.0763817964,percent_activity,1.90308998699194,24.2787965463124,,1.42314247947495,1.36466619642591,1.3361180874388,20,cell cycle
TOX21_RT_HEK293_GLO_16hr_viability,"TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,83.5066885788038,3.464109171282744,30.120366276688866,1.47886024876962,4.0177086637968,83.4127401739,percent_activity,1.90308998699194,24.1062519827808,,1.422550151786,1.36773467495529,1.34166600943443,20,cell cycle
TOX21_RT_HEK293_GLO_24hr_viability,"TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,85.6713645457586,3.4917786935587416,30.74962202288803,1.48783978175752,4.08919407864135,85.5729322184,percent_activity,1.90308998699194,24.5351644718481,,1.43182917577178,1.3780871182556,1.35304425850795,20,cell cycle
TOX21_RT_HEK293_GLO_32hr_viability,"TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,90.2887190535273,3.5939529312283445,30.532289877992422,1.48475937698399,4.18706647811088,89.9484521386,percent_activity,1.90308998699194,25.1223988686653,,1.41336030302686,1.34823603770105,1.32017418201787,20,cell cycle
TOX21_RT_HEK293_GLO_40hr_viability,"TOX21_RT_HEK293_GLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,89.6802118675591,3.6008378118506155,31.70220798412827,1.50108951085905,4.15089564121323,89.2806082348,percent_activity,1.90308998699194,24.9053738472794,,1.43008963408158,1.36554085780672,1.33787839377729,20,cell cycle
TOX21_RT_HEPG2_FLO_08hr_viability,"TOX21_RT_HEPG2_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,113.788573878181,4.044695357468376,59.04824290455212,1.77120697886383,4.68879869481702,94.8353077663,percent_activity,1.90308998699194,28.1327921689021,,1.68000585501034,1.61077377400677,1.59122745852411,20,cell cycle
TOX21_RT_HEPG2_FLO_16hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,121.738374210098,4.403318692994054,37.59107384476226,1.57508473215684,4.60782660753093,178.1544277786,percent_activity,-2.69897000433602,27.6469596451856,"[""Noisy data"",""Noisy data""]",1.48699052676471,1.4272740150852,1.41704220219551,20,cell cycle
TOX21_RT_HEPG2_FLO_24hr_viability,"TOX21_RT_HEPG2_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,171.518500107611,6.252943687252307,37.12863798163258,1.56970901796005,4.57167345723585,363.5249601694,percent_activity,-2.69897000433602,27.4300407434151,"[""Noisy data"",""Noisy data""]",1.47965055914074,1.43708205135888,1.45041795428023,20,cell cycle
TOX21_RT_HEPG2_FLO_32hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,224.353732247353,7.662154603809653,44.16997300013574,1.64512713378645,4.88012714978376,213.9456199588,percent_activity,1.90308998699194,29.2807628987026,,1.48330501548635,1.41798416095622,1.45763953434359,20,cell cycle
TOX21_RT_HEPG2_FLO_40hr_ctrl_viability,"TOX21_RT_HEPG2_FLO_40hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,235.820250585363,8.757249038521408,38.345506309638445,1.58371447651771,4.48809608184861,235.1642399184,percent_activity,1.90308998699194,26.9285764910917,,1.47250100965193,1.43148130405479,1.4644341627467,20,cell cycle
TOX21_RT_HEPG2_GLO_08hr_ctrl_viability,"TOX21_RT_HEPG2_GLO_08hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,61.9934029601224,3.09967014800612,36.466114013409474,1.561889485484,1.79765049419046,61.8501383213,percent_activity,1.90308998699194,20,,1.52162060127021,1.43426531271011,1.44260917180357,20,cell cycle
TOX21_RT_HEPG2_GLO_16hr_ctrl_viability,"TOX21_RT_HEPG2_GLO_16hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,77.8032008522059,3.890160042610295,49.39584494548831,1.69369041869814,1.42693580835246,64.8360007218,percent_activity,1.90308998699194,20,,1.55540995612365,1.32321180015786,1.40740960243271,20,cell cycle
TOX21_RT_HEPG2_GLO_24hr_ctrl_viability,"TOX21_RT_HEPG2_GLO_24hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,31.2563435160784,1.56281717580392,43.00809181127373,1.63355017414632,1.22724010465665,31.0398221855,percent_activity,1.90308998699194,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.66475426094146,1.52424280886068,1.51426984281959,20,cell cycle
TOX21_RT_HEPG2_GLO_32hr_ctrl_viability,"TOX21_RT_HEPG2_GLO_32hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,63.4756004568934,3.17378002284467,44.18092693954301,1.64523482336216,1.38797001670782,61.3255965361,percent_activity,1.90308998699194,20,,1.58548178769219,1.44081536156472,1.47614748622177,20,cell cycle
TOX21_RT_HEPG2_GLO_40hr_viability,"TOX21_RT_HEPG2_GLO_40hr_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,67.2527536520463,3.3626376826023145,58.88373309722933,1.76999533550291,1.78454044898115,56.0439622054,percent_activity,1.90308998699194,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.69887887169853,1.56753146902106,1.58825223122235,20,cell cycle
TOX21_RXR_BLA_Agonist_viability,"TOX21_RXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,85.8310267484944,3.2230644186342743,50.473515868854605,1.70306355774063,4.43837580224682,64.5204181352,percent_activity,1.90308998699194,26.6302548134809,,1.56841628253123,1.41739805374445,1.33273528133783,20,cell cycle
TOX21_SBE_BLA_Agonist_viability,"The assay component endpoint  TOX21_SBE_BLA_Agonist_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,50.7494241523505,1.7160904542985946,34.83677669889,1.5420379647442,4.92878294237826,48.8702551886,percent_activity,1.90308998699194,29.5726976542696,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.56514088314497,1.48055067846021,1.39003172286863,20,cell cycle
TOX21_TRHR_HEK293_Agonist,"TOX21_TRHR_HEK293_Agonist  used a type of biochemical reporter where gain-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",, , , ,,,Active,33.5346293814426,1.67673146907213,26.97031260593844,1.43088598027741,0.23532099546207,27.6092872562,percent_activity,1.77815125038364,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.55897795106699,0.171391245190684,0.710115907589665,20,gpcr
TOX21_TRHR_HEK293_Antagonist,"TOX21_TRHR_HEK293_Antagonist  used a type of biochemical reporter where loss-of-signal activity can be used to understand changes in the receptor activation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",, , , ,,,Active,41.0349572801074,2.05174786400537,38.59655441894161,1.58654853618389,2.87526712790688,25.4049512488,percent_activity,1.77815125038364,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.56125592672829,0.92297796756436,0.485066193023046,20,gpcr
TOX21_TR_LUC_GH3_Antagonist,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_003241.2|NP_000452.2", , , ,,,Active,124.698796000722,5.557794097893638,45.1685231871318,1.65483589126619,3.73945711206963,103.4729971294,percent_activity,1.95424250943932,22.4367426724178,,1.38780745875952,1.24745935433726,1.26803048269992,20,nuclear receptor
TOX21_TR_LUC_GH3_Antagonist_viability,"TOX21_TR_LUC_GH3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,105.992160456849,2.644822132651247,46.12853435604023,1.66396965596972,6.67922423139783,91.9372166019,percent_activity,1.95424250943932,40.075345388387,,1.58682440896969,1.43822222521161,1.32334576766318,20,cell cycle
TOX21_TSHR_HTRF_Agonist_ratio,"Data from the assay component TOX21_TSHR_HTRF_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",, , , ,,,Active,72.6058876332319,2.6072431779623795,11.077755976921559,1.0444517941882,4.64129367543786,70.993926952,percent_activity,1.95424250943932,27.8477620526272,,0.910042802708262,0.636985517338698,0.422082893268514,20,gpcr
TOX21_VDR_BLA_Agonist_viability,"TOX21_VDR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,87.7984070426588,3.2290704069448224,33.67935000920557,1.52736370129141,4.53166577259249,89.0825563427,percent_activity,1.90308998699194,27.1899946355549,,1.48384822786748,1.4352331090107,1.40808338721363,20,cell cycle